The market for anaplastic lymphoma kinase (ALK) inhibitors is projected to expand in the coming years, fueled by an ...

Research from AARP has found that around $1100 in prescription drug costs could be saved by more than a million seniors, due ...

The Danish Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in ...

Novo Nordisk’s semaglutide—marketed under the names Wegovy and Ozempic—have already shown their potential to treat diabetes, ...

Japan’s Nxera Pharma (TYO 4565) today announced that it will receive a $35 million payment from Neurocrine Biosciences ...

Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) ...

Sanofi (Euronext: SAN) has announced results from the HERCULES Phase III study, with BTK blocker tolebrutinib meeting the ...

Cytokinetics (Nasdaq: CYTK) has presented new data on aficamten, its experimental cardiac myosin inhibitor, at the European ...

German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto ...

Belgian drugmaker UCB (Euronext: UCB) has appointed Nico Reynders as general manager of its UK & Ireland affiliate. In this ...

UK-based George Medicines has announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London.

US biotech Arrowhead Pharmaceuticals has unveiled highly anticipated pancreatitis results from a late-stage trial of plozasiran, several months after reporting top-line data.